Affiliation: The Netherlands Cancer Institute
Country: The Netherlands
- Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCISN Bijker
Department of Radiation Oncology, The Netherlands Cancer Institute Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
Br J Cancer 87:615-20. 2002..Selection of patients may explain the differences in outcome of the randomised patients, and those not-entered. Thus, the results of this trial may not be applicable to all patients with ductal carcinoma in situ...
- Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group andNina Bijker
Department of Radiation Oncology, Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands
J Clin Oncol 24:3381-7. 2006..We analyzed the efficacy of RT with 10 years follow-up on both the overall risk of local recurrence (LR) and related to clinical, histologic, and treatment factors...
- Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situN Bijker
Department of Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, CX, 1066, The Netherlands
Br J Cancer 84:539-44. 2001....
- Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853N Bijker
Departments of Radiation Oncology and Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
J Clin Oncol 19:2263-71. 2001..Margin status is the most important factor in the success of BCT for DCIS; additionally, young age and symptomatic detection of DCIS have negative prognostic value...
- Variations in diagnostic and therapeutic procedures in a multicentre, randomized clinical trial (EORTC 10853) investigating breast-conserving treatment for DCISN Bijker
Department of Pathology, The Netherlands Cancer Institute Antoni van Leeuwenhoek ziekenhuis, Amsterdam, The Netherlands
Eur J Surg Oncol 27:135-40. 2001..The risk of local recurrence in itself, and hence the success of BCT for DCIS, may however be influenced by the quality of the initial procedures that were conducted...
- Ductal carcinoma in situ of the breast; diagnostic assessment and treatmentE J Th Rutgers
Department of Surgery, Pathology, and Radiation Oncology, Netherlands Cancer Institute, Amsterdam
Scand J Surg 91:268-72. 2002
- Is DCIS breast cancer, and how do I treat it?N Bijker
Department of Radiation Oncology, Academic Medical Center, P O Box 22700, 1100DE, Amsterdam, The Netherlands
Curr Treat Options Oncol 14:75-87. 2013....
- Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breastLawrence J Solin
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Cancer 103:1137-46. 2005..The objective of the current study was to determine the long-term outcome after breast-conservation surgery followed by definitive breast irradiation for women with mammographically detected DCIS of the breast...
- Salvage treatment for local or local-regional recurrence after initial breast conservation treatment with radiation for ductal carcinoma in situLawrence J Solin
Department of Radiation Oncology, University of Pennsylvania School of Medicine, 3400 Spruce Street, Philadelphia, PA 19104, USA
Eur J Cancer 41:1715-23. 2005..Close follow-up after initial breast conservation treatment with radiation is warranted for the early detection of potentially salvageable local and local-regional recurrences...